Targeting metastatic breast cancer

靶向转移性乳腺癌

• 批准号: 455849
• 负责人: Anderson Deborah H
• 金额: $ 7.29万
• 依托单位: University of Saskatchewan
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-09-01 至 2022-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=455849&lang=en
• 关键词: Drug Discovery; Efficacy In Mouse Xenografts And Patient-Derived Xenografts; Ic50; Medicinal Chemistry; New Treatments; Pharmacokinetics; Physiochemical Properties; Structure-Activity Relationships; Toxicities And Dosing Regimen; Triple Negative Breast Ca

Breast cancer affects one in nine Canadian women and those with metastatic breast cancer have a disheartening five-year survival rate of only 28%. Triple negative breast cancers lack the receptors for estrogen, progesterone and HER2 that are present in ot

乳腺癌影响着九分之一的加拿大女性，而转移性乳腺癌患者的五年生存率仅为 28%，令人沮丧。三阴性乳腺癌缺乏存在于其他组织中的雌激素、孕激素和 HER2 受体